PERRONE, FEDERICA
 Distribuzione geografica
Continente #
NA - Nord America 22
AS - Asia 13
EU - Europa 13
Totale 48
Nazione #
US - Stati Uniti d'America 22
SE - Svezia 6
SG - Singapore 6
CN - Cina 4
IT - Italia 4
JP - Giappone 2
FI - Finlandia 1
IE - Irlanda 1
PH - Filippine 1
RU - Federazione Russa 1
Totale 48
Città #
Boardman 5
Shanghai 4
Singapore 4
Ashburn 3
Milan 3
New York 2
Seattle 2
Tokyo 2
Dublin 1
Helsinki 1
Lawrence 1
Princeton 1
Tarlac City 1
Totale 30
Nome #
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial 28
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer 10
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 6
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 5
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review 4
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review 2
Totale 55
Categoria #
all - tutte 446
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 446


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221 0 0 0 0 0 0 0 1 0 0 0 0
2022/202311 3 2 1 0 0 1 2 0 2 0 0 0
2023/202435 0 1 6 4 1 4 0 2 0 1 8 8
2024/20258 8 0 0 0 0 0 0 0 0 0 0 0
Totale 55